Last reviewed · How we verify
Tilidate (TILIDINE)
Tilidate (generic name: TILIDINE) is a drug. It is currently FDA-approved for Pain.
Tilidate, also known as Tilidine, is a small molecule drug that targets the Mu-type opioid receptor. It is classified as a tilidine and is used to treat pain. The commercial status of Tilidate is unknown, but it is not FDA-approved. Key safety considerations include its potential for dependence and abuse. Tilidate has a half-life of 5.0 hours and a bioavailability of 90%.
At a glance
| Generic name | TILIDINE |
|---|---|
| Target | Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Pain
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tilidate CI brief — competitive landscape report
- Tilidate updates RSS · CI watch RSS
Frequently asked questions about Tilidate
What is Tilidate?
Tilidate (TILIDINE) is a Small molecule drug, indicated for Pain.
What is Tilidate used for?
Tilidate is indicated for Pain.
What is the generic name of Tilidate?
TILIDINE is the generic (nonproprietary) name of Tilidate.
What development phase is Tilidate in?
Tilidate is FDA-approved (marketed).
What does Tilidate target?
Tilidate targets Mu-type opioid receptor.
Related
- Target: All drugs targeting Mu-type opioid receptor
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Pain